THERAPEUTIC STRATEGIES FOR MICROVASCULAR DYSFUNCTION IN TYPE 1 DIABETES

MCD-1 Study Purpose-The purpose of this study is to look at how insulin (a hormone that helps the cells get energy from sugar) affects blood flow in the leg and in the heart and how an investigational drug called dulaglutide affects insulin’s action. We also want to see if dulaglutide improves the health of blood vessels by measuring blood vessels’ stiffness and how they react to certain stimuli.
Study Duration-18 - 20 weeks
Study Commitment-• 1 Screening Visit
• 5 Outpatient visits
• 2 8-hr Outpatient stays
Age-18-40 years old
Sex-Male and Female
Conditions/Eligibility-Male or females, ≥18 years old and ≤40 years old, with Type 1 diabetes and are otherwise healthy
Study Procedures-• Physical exam, vital signs, height, weight, BMI, screening labs, urine screen, Pregnancy test (if applicable), measurement of waist and hip circumference, EKG
• Continuous glucose monitor (CGM) application
• DEXA
• Medical and medication history
• ActiGraph Monitor
• Exercise glucose plans
• Surveys/Questionnaires
• Glucose/insulin logs
• VO2max Exercise Testing
• Augmentation Index (AI)
• Pulse Wave Velocity (PWV)
• Flow mediated Dilation (FMD)
• Contrast enhanced ultrasound (CEU)
• Near infrared spectroscopy (NIRS)
• Endothelial cell harvest (EC)
• Euglycemic insulin clamp
• Administration of Dulaglutide or placebo
• Multiple blood draws and urine collections
Compensation-$1800